Dupilumab for the treatment of adults with moderate to severe prurigo nodularis

NICE

13 March 2024 - NICE has published final evidence-based recommendations on the use of dupilumab (Dupixent) for the treatment of adults with moderate to severe prurigo nodularis.

Dupilumab is not recommended for the treatment of adults with moderate to severe prurigo nodularis when systemic treatment is suitable.

Read NICE technology appraisal guidance

Michael Wonder

Posted by:

Michael Wonder